126 related articles for article (PubMed ID: 11816018)
1. Canine prostate induces new bone formation in mouse calvaria: A model of osteoinduction by prostate tissue.
LeRoy BE; Bahnson RR; Rosol TJ
Prostate; 2002 Feb; 50(2):104-11. PubMed ID: 11816018
[TBL] [Abstract][Full Text] [Related]
2. New bone formation in nude mouse calvaria induced by canine prostate tissue.
LeRoy BE; Bahnson RR; Rosol TJ
Mol Cell Endocrinol; 2002 Nov; 197(1-2):257-63. PubMed ID: 12431820
[TBL] [Abstract][Full Text] [Related]
3. Canine prostate stimulates osteoblast function using the endothelin receptors.
LeRoy BE; Sellers RS; Rosol TJ
Prostate; 2004 May; 59(2):148-56. PubMed ID: 15042615
[TBL] [Abstract][Full Text] [Related]
4. Animal models of bone metastasis.
Rosol TJ; Tannehill-Gregg SH; LeRoy BE; Mandl S; Contag CH
Cancer; 2003 Feb; 97(3 Suppl):748-57. PubMed ID: 12548572
[TBL] [Abstract][Full Text] [Related]
5. Spiculated periosteal response induced by intraosseous injection of 22Rv1 prostate cancer cells resembles subset of bone metastases in prostate cancer patients.
Henry MD; Silva MD; Wen S; Siebert E; Solin E; Chandra S; Worland PJ
Prostate; 2005 Dec; 65(4):347-54. PubMed ID: 16032708
[TBL] [Abstract][Full Text] [Related]
6. Use of zoledronate to treat osteoblastic versus osteolytic lesions in a severe-combined-immunodeficient mouse model.
Lee YP; Schwarz EM; Davies M; Jo M; Gates J; Zhang X; Wu J; Lieberman JR
Cancer Res; 2002 Oct; 62(19):5564-70. PubMed ID: 12359769
[TBL] [Abstract][Full Text] [Related]
7. Zoledronic acid decreased osteolysis but not bone metastasis in a nude mouse model of canine prostate cancer with mixed bone lesions.
Thudi NK; Martin CK; Nadella MV; Fernandez SA; Werbeck JL; Pinzone JJ; Rosol TJ
Prostate; 2008 Jul; 68(10):1116-25. PubMed ID: 18461562
[TBL] [Abstract][Full Text] [Related]
8. Canine prostatic cancer cell line (LuMa) with osteoblastic bone metastasis.
Elshafae SM; Dirksen WP; Alasonyalilar-Demirer A; Breitbach J; Yuan S; Kantake N; Supsavhad W; Hassan BB; Attia Z; Alstadt LB; Rosol TJ
Prostate; 2020 Jun; 80(9):698-714. PubMed ID: 32348616
[TBL] [Abstract][Full Text] [Related]
9. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
10. New bone formation and osteolysis by a metastatic, highly invasive canine prostate carcinoma xenograft.
LeRoy BE; Thudi NK; Nadella MV; Toribio RE; Tannehill-Gregg SH; van Bokhoven A; Davis D; Corn S; Rosol TJ
Prostate; 2006 Aug; 66(11):1213-22. PubMed ID: 16683269
[TBL] [Abstract][Full Text] [Related]
11. Intraosseous growth of human prostate cancer in implanted adult human bone: relationship of prostate cancer cells to osteoclasts in osteoblastic metastatic lesions.
Yonou H; Ochiai A; Goya M; Kanomata N; Hokama S; Morozumi M; Sugaya K; Hatano T; Ogawa Y
Prostate; 2004 Mar; 58(4):406-13. PubMed ID: 14968441
[TBL] [Abstract][Full Text] [Related]
12. CD169(+) macrophages mediate pathological formation of woven bone in skeletal lesions of prostate cancer.
Wu AC; He Y; Broomfield A; Paatan NJ; Harrington BS; Tseng HW; Beaven EA; Kiernan DM; Swindle P; Clubb AB; Levesque JP; Winkler IG; Ling MT; Srinivasan B; Hooper JD; Pettit AR
J Pathol; 2016 Jun; 239(2):218-30. PubMed ID: 27174786
[TBL] [Abstract][Full Text] [Related]
13. Severe combined immunodeficient-hu model of human prostate cancer metastasis to human bone.
Nemeth JA; Harb JF; Barroso U; He Z; Grignon DJ; Cher ML
Cancer Res; 1999 Apr; 59(8):1987-93. PubMed ID: 10213511
[TBL] [Abstract][Full Text] [Related]
14. The bisphosphonate YM529 inhibits osteoblastic bone tumor proliferation of prostate cancer.
Yonou H; Ochiai A; Ashimine S; Maeda H; Horiguchi Y; Yoshioka K; Ogawa Y; Hatano T; Tachibana M
Prostate; 2007 Jun; 67(9):999-1009. PubMed ID: 17440967
[TBL] [Abstract][Full Text] [Related]
15. Prostate-specific antigen induces apoptosis of osteoclast precursors: potential role in osteoblastic bone metastases of prostate cancer.
Goya M; Ishii G; Miyamoto S; Hasebe T; Nagai K; Yonou H; Hatano T; Ogawa Y; Ochiai A
Prostate; 2006 Nov; 66(15):1573-84. PubMed ID: 16927388
[TBL] [Abstract][Full Text] [Related]
16. Angiogenesis inhibitor TNP-470 inhibits human breast cancer osteolytic bone metastasis in nude mice through the reduction of bone resorption.
Sasaki A; Alcalde RE; Nishiyama A; Lim DD; Mese H; Akedo H; Matsumura T
Cancer Res; 1998 Feb; 58(3):462-7. PubMed ID: 9458090
[TBL] [Abstract][Full Text] [Related]
17. Intraosseous injection of RM1 murine prostate cancer cells promotes rapid osteolysis and periosteal bone deposition.
McCabe NP; Madajka M; Vasanji A; Byzova TV
Clin Exp Metastasis; 2008; 25(5):581-90. PubMed ID: 18506587
[TBL] [Abstract][Full Text] [Related]
18. Expression of macrophage inhibitory cytokine-1 in prostate cancer bone metastases induces osteoclast activation and weight loss.
Wakchoure S; Swain TM; Hentunen TA; Bauskin AR; Brown DA; Breit SN; Vuopala KS; Harris KW; Selander KS
Prostate; 2009 May; 69(6):652-61. PubMed ID: 19152406
[TBL] [Abstract][Full Text] [Related]
19. The effects of RANK blockade and osteoclast depletion in a model of pure osteoblastic prostate cancer metastasis in bone.
Whang PG; Schwarz EM; Gamradt SC; Dougall WC; Lieberman JR
J Orthop Res; 2005 Nov; 23(6):1475-83. PubMed ID: 16005175
[TBL] [Abstract][Full Text] [Related]
20. Establishment of a model to evaluate inhibition of bone resorption induced by human prostate cancer cells in nude mice.
Nemoto R; Kanoh S; Koiso K; Harada M
J Urol; 1988 Oct; 140(4):875-9. PubMed ID: 3138435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]